{"id":563840,"date":"2021-09-16T15:08:01","date_gmt":"2021-09-16T15:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=563840"},"modified":"2021-09-16T15:08:01","modified_gmt":"2021-09-16T15:08:01","slug":"the-hodgkins-lymphoma-market-size-is-anticipated-to-grow-during-the-study-period-201830-owing-to-the-launch-of-upcoming-therapies-such-as-tislelizumab-adct301-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-hodgkins-lymphoma-market-size-is-anticipated-to-grow-during-the-study-period-201830-owing-to-the-launch-of-upcoming-therapies-such-as-tislelizumab-adct301-and-others_563840.html","title":{"rendered":"The Hodgkin\u2019s Lymphoma market size is anticipated to grow during the study period (2018-30) owing to the launch of upcoming therapies such as Tislelizumab, ADCT-301, and others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631780217.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The Hodgkin&rsquo;s Lymphoma market size is anticipated to grow during the study period (2018-30) owing to the launch of upcoming therapies such as Tislelizumab, ADCT-301, and others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1631780217.png\" alt=\"The Hodgkin&rsquo;s Lymphoma market size is anticipated to grow during the study period (2018-30) owing to the launch of upcoming therapies such as Tislelizumab, ADCT-301, and others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Hodgkin&#8217;s Lymphoma Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Hodgkin\u2019s Lymphoma market size is anticipated to increase due to the launch of the upcoming therapies such as ADCT-301, Tislelizumab, Autologous CD30, and others during the forecast period (2021-30).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/75567f1a918102b1febd92a73e6076c6.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-hl-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Hodgkin&rsquo;s Lymphoma market report<\/a><\/strong> provides a comprehensive understanding of the Hodgkin&rsquo;s Lymphoma, historical and forecasted epidemiology, as well as Hodgkin&rsquo;s Lymphoma market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). The report also proffers an analysis of the current Hodgkin&rsquo;s Lymphoma treatment practice\/algorithm, Hodgkin&rsquo;s Lymphoma market drivers, Hodgkin&rsquo;s Lymphoma market barriers, and unmet medical needs.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Hodgkin&rsquo;s Lymphoma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the National Organization for Rare Diseases (NORD), most people with the adult form of Hodgkin&#8217;s disease are between the ages of <strong>15 and 40<\/strong> when they are diagnosed.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the American Cancer Society estimates, there will be <strong>8,830<\/strong> new cases of Hodgkin Lymphoma in the United States in 2021.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key companies such as <strong>ADC Therapeutics, BeiGene, Tessa Therapeutics,<\/strong> and others are expected to enter the Hodgkin&rsquo;s Lymphoma market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key emerging Hodgkin&rsquo;s Lymphoma therapies include <strong>ADCT-301, Tislelizumab, Autologous CD30,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Camidanlumab Tesirine (ADCT-301)<\/strong> is being developed and evaluated in phase II clinical trial by ADC Therapeutics for the Relapsed\/Refractory Hodgkin Lymphoma (R\/R HL).&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Tislelizumab (BGB-A317),<\/strong> developed by BeiGene, is a humanized IgG4 anti-PD-1 monoclonal antibody under investigation that is specifically designed to reduce binding to FcR on macrophages.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Request for the Webex demo of the report @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-hl-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Hodgkin&rsquo;s Lymphoma Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Hodgkin&#8217;s Lymphoma market report<\/strong> also covers current treatment practices, emerging drugs, Hodgkin&#8217;s Lymphoma market share of individual therapies, and current and forecasted Hodgkin&#8217;s Lymphoma market Size from 2018 to 2030, segmented by seven major markets.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Hodgkin&#8217;s Lymphoma is a type of lymphoma. Lymphoma is a broad term for cancers that affect the lymphatic system, particularly the lymph nodes. Tumors frequently form in the lymph nodes and the surrounding area. It has been discovered through preliminary research that a variety of factors can cause Hodgkin Lymphoma. These are caused by a contagious agent, such as a virus (e.g., Epstein Barr Virus).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Hodgkin&rsquo;s Lymphoma report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hodgkin&rsquo;s Lymphoma Total Incident Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hodgkin&rsquo;s Lymphoma Age-Specific Incident Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hodgkin&rsquo;s Lymphoma Gender-Specific Incident Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Relapsed\/Refractory Hodgkin&rsquo;s Lymphoma Incident Population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Relapsed\/Refractory Hodgkin&rsquo;s Lymphoma Treatable Cases<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The main treatment options for Hodgkin&rsquo;s Lymphoma are <strong>Chemotherapy and radiation therapy.<\/strong> Apart from this, some FDA-approved such as <strong>Brentuximab vedotin (Adcetris), Rituximab (Rituxan), Nivolumab (Opdivo), and pembrolizumab (Keytruda)<\/strong> are also used to treat Hodgkin&rsquo;s Lymphoma.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Hodgkin&rsquo;s Lymphoma market size is anticipated to increase due to the launch of the upcoming therapies such as ADCT-301, Tislelizumab, Autologous CD30, and others by key companies like ADC Therapeutics, BeiGene, Tessa Therapeutics, and others during the forecast period (2021-30).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get the detailed analysis of the upcoming therapies @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-hl-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Hodgkin&rsquo;s Lymphoma Pipeline Therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">ADCT-301: ADC Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tislelizumab: BeiGene<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Autologous CD30: Tessa Therapeutics&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period:<\/strong> 2018-30<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma Key Companies:<\/strong> ADC Therapeutics, BeiGene, Tessa Therapeutics, among others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma Key Pipeline Therapies:<\/strong> ADCT-301, Tislelizumab, Autologous CD30, and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hodgkin&rsquo;s Lymphoma Segmentation:<\/strong> By Geography, By Hodgkin&rsquo;s Lymphoma therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis:<\/strong> Comparative and conjoint analysis of Hodgkin&rsquo;s Lymphoma emerging therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used:<\/strong> SWOT Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"83\" \/>\n<col width=\"541\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma: Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disease Background and Overview: Hodgkin Lymphoma&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma Epidemiology and Patient Population (7MM)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma: Country-Wise Epidemiology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma Treatments &amp; Medical Practices<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma: Market Size&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma 7MM: Country-Wise Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma United States Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma EU5 Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma Japan Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Hodgkin Lymphoma Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of CAR T-Cell Therapy for Non-Hodgkin Lymphoma pipeline therapies and key companies such as <strong>Novartis, Gilead Sciences,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-hodgkins-lymphoma-market-size-is-anticipated-to-grow-during-the-study-period-201830-owing-to-the-launch-of-upcoming-therapies-such-as-tislelizumab-adct301-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-hodgkins-lymphoma-market-size-is-anticipated-to-grow-during-the-study-period-201830-owing-to-the-launch-of-upcoming-therapies-such-as-tislelizumab-adct301-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hodgkin&#8217;s Lymphoma Market The Hodgkin\u2019s Lymphoma market size is anticipated to increase due to the launch of the upcoming therapies such as ADCT-301, Tislelizumab, Autologous CD30, and others during the forecast period (2021-30). DelveInsight&rsquo;s Hodgkin&rsquo;s Lymphoma market report provides a &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-hodgkins-lymphoma-market-size-is-anticipated-to-grow-during-the-study-period-201830-owing-to-the-launch-of-upcoming-therapies-such-as-tislelizumab-adct301-and-others_563840.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-563840","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/563840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=563840"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/563840\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=563840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=563840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=563840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}